Antimicrobial resistance comparison of Klebsiella pneumoniae pathogens isolated from intra-abdominal and urinary tract infections in different organs, hospital departments and regions of China between 2014 and 2017

被引：20
作者：
Zhang, Hui [1 ]
Zhang, Ge [1 ]
Yang, Yang [1 ]
Zhang, Jingjia [1 ]
Li, Dongxue [1 ]
Duan, Simeng [1 ]
Yang, Qiwen [1 ]
Xu, Yingchun [1 ]
机构：
[1] Peking Union Med Coll Hosp, Chinese Acad Med Sci, Peking Union Med Coll, Div Microbiol, 1 Shuaifuyuan, Beijing 100730, Peoples R China
来源：
JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION | 2021年 / 54卷 / 04期
关键词：
Klebsiella pneumoniae; Urinary tract infections; Intra-abdominal infections; Carbapenems; ESBL; Antibiotic resistance; GRAM-NEGATIVE BACILLI; CLINICAL EPIDEMIOLOGY; TRENDS SMART;
D O I：
10.1016/j.jmii.2020.03.009
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Background: We describe antibiotic resistance trends of Klebsiella pneumoniae pathogens, responsible for urinary tract infections (UTIs) and intra-abdominal infections (IAIs), isolated from different organs and tissues, hospital departments and Chinese regions between 2014 and 2017. Methods: Resistances of UTIs and IAIs derived K. pneumoniae isolates from 17 hospitals in 7 Chinese regions to amikacin, imipenem, piperacillin-tazobactam, ertapenem, and cefepime were unequivocally established. Results: Overall resistance rates of K. pneumoniae IAI isolates obtained from gallbladder and abscesses increased to amikacin (14.29-30.95%) and for liver, gallbladder, and abscesses to imipenem (14.29-38.10%), piperacillin-tazobactam (23.81-38.10%), and ertapenem (23.81-38 .10%) in 2017, but were constant (20-30%) for K. pneumoniae isolates from UTIs from 2014 to 2017. In medical and surgical ICUs, resistance rates to all tested antibiotics rose to w60% for IAIs, which was also reflected in higher resistance rates of hospital acquired (HA) compared to community acquired (CA) infections. In medical ICUs resistance rates increased to 50-60% for amikacin, imipenem, and ertapenem for UTI-derived K. pneumoniae isolates in 2017. Resistance rates to all tested antibiotics were highest in the east Jiangzhe region of China, being w60% for K. pneumoniae isolates from IAIs and 40% for K. pneumoniae isolates from UTIs to ertapenem and imipenem, as well as > 40% for piperacillin-tazobactam in 2017. Conclusion: In China, ICUs resistance rates to K. pneumoniae IAIs and UTIs isolates was increased in 2017 for all tested antimicrobials including carbapenems, which makes them no longer suitable for empiric treatment. In the east Jiangzhe region this was a general trend that was independent of the type of hospital department. Copyright 2020, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/bync-nd/4.0/).
引用
收藏
页码：639 / 648
页数：10
相关论文
共 21 条
  • [1] Empiric antibiotic therapy in urinary tract infection in patients with risk factors for antibiotic resistance in a German emergency department[J]. Bischoff, Sebastian;Walter, Thomas;Gerigk, Marlis;Ebert, Matthias;Vogelmann, Roger. BMC INFECTIOUS DISEASES, 2018
  • [2] Two cases of monomicrobial intraabdominal abscesses due to KPC-3 Klebsiella pneumoniae ST258 clone[J]. Di Carlo, Paola;Pantuso, Gianni;Cusimano, Alessia;D'Arpa, Francesco;Giammanco, Anna;Gulotta, Gaspare;Latteri, Adelfio M.;Madonia, Simona;Salamone, Giuseppe;Mammina, Caterina. BMC GASTROENTEROLOGY, 2011
  • [3] Recommendations in the empiric anti-infective agents of intra-abdominal infection[J]. Guirao, Xavier;Arias, Javier;Badia, Josep Ma;Garcia-Rodriguez, Jose A.;Mensa, Jose;Alvarez-Lerma, Francisco;Borges, Marcio;Barberan, Jose;Maseda, Emilio;Salavert, Miguel;Llinares, Pedro;Gobernado, Miguel;Garcia Rey, Cesar. CIRUGIA ESPANOLA, 2010(02)
  • [4] Emergence of High Levels of Extended-Spectrum-β-Lactamase-Producing Gram-Negative Bacilli in the Asia-Pacific Region: Data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) Program, 2007[J]. Hawser, Stephen P.;Bouchillon, Samuel K.;Hoban, Daryl J.;Badal, Robert E.;Hsueh, Po-Ren;Paterson, David L. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009(08)
  • [5] Institute CaLS, 2013, PERFORMANCE STANDARD, V23th, P2013
  • [6] Institute CaLS, 2016, M100S CLSI, V26th, P2016
  • [7] Clinical epidemiology of Klebsiella pneumoniae carbapenemases[J]. Lippmann, Norman;Luebbert, Christoph;Kaiser, Thorsten;Kaisers, Udo X.;Rodloff, Arne C. LANCET INFECTIOUS DISEASES, 2014(04)
  • [8] A Review of Ten Years of the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2002 to 2011[J]. Morrissey, Ian;Hackel, Meredith;Badal, Robert;Bouchillon, Sam;Hawser, Stephen;Biedenbach, Douglas. PHARMACEUTICALS, 2013(11)
  • [9] Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases[J]. Munoz-Price, L. Silvia;Poirel, Laurent;Bonomo, Robert A.;Schwaber, Mitchell J.;Daikos, George L.;Cormican, Martin;Cornaglia, Giuseppe;Garau, Javier;Gniadkowski, Marek;Hayden, Mary K.;Kumarasamy, Karthikeyan;Livermore, David M.;Maya, Juan J.;Nordmann, Patrice;Patel, Jean B.;Paterson, David L.;Pitout, Johann;Villegas, Maria Virginia;Wang, Hui;Woodford, Neil;Quinn, John P. LANCET INFECTIOUS DISEASES, 2013(09)
  • [10] Pana Zoi Dorothea, 2018, F1000Res, V7, DOI 10.12688/f1000research.14822.1
123